PMID- 26727137
OWN - NLM
STAT- MEDLINE
DCOM- 20160401
LR  - 20160105
IS  - 0021-4884 (Print)
IS  - 0021-4884 (Linking)
VI  - 64
IP  - 10
DP  - 2015 Dec
TI  - [CLINICAL EFFICACY OF SUBLINGUAL IMMUNOTHERAPY FOR JAPANESE CEDAR POLLINOSIS IN 
      THE FIRST FOLLOW-UP YEAR].
PG  - 1323-33
LID - 10.15036/arerugi.64.1323 [doi]
AB  - The first drug of sublingual immunotherapy (SLIT) for Japanese Cedar pollinosis 
      (JCP) was purchased in 2014.   PURPOSE: The purpose of this study is to clear the 
      clinical efficacy of SLIT by comparing with other therapies, such as subcutaneous 
      immunotherapy (SCIT), or other pharmacotherapy.   METHODS: We started SLIT at our 
      clinic in October-December, 2014. We compared the clinical efficacy of 191 SLIT 
      with 48 SCIT, 191 primary pharmacotherapy that started therapies before pollen 
      dispersal, 141 pharmacotherapy that started therapies after pollen disposal, or 
      169 non-treatment in the first follow-up year. The clinical efficacy was 
      evaluated with quality of life (QOL) scores by Japanese rhino-conjunctivitis QOL 
      questionnaire (JRQLQ No1), symptoms of nose and eye by visual analog scale (VAS), 
      symptom scores and combined symptom-medication scores (SMS).   RESULTS: Mild 
      adverse events (AEs) were observed in many cases, but no patient was discontinued 
      by AEs in SLIT patients. Five cases by unknown reasons and 3 cases by inevitable 
      reasons were dropped out before pollen. Adherence of SLIT was 89+/-12%. SCIT was 
      better than SLIT in most assessments, but not significant. Both SCIT and SLIT 
      were significantly better than other pharmacotherapy. Patients, whose symptom 
      scores of nose and eye were 0 or 1 point without any rescue drugs, accounted for 
      16.8% of total SLIT in the first follow-up year.   CONCLUSION: SCIT was slightly 
      better than SLIT in reducing symptoms and SMS of JCP, and in improving QOL. 
      However, the differences were not significant. SLIT was significantly effective 
      than other pharmacotherapies.
FAU - Yuta, Atsushi
AU  - Yuta A
AD  - Yuta Clinic.
FAU - Ogawa, Yukiko
AU  - Ogawa Y
FAU - Suzuki, Yusuke
AU  - Suzuki Y
FAU - Arikata, Masahiko
AU  - Arikata M
FAU - Kozaki, Hideaki
AU  - Kozaki H
FAU - Shimizu, Takeshi
AU  - Shimizu T
FAU - Ohta, Nobuo
AU  - Ohta N
LA  - jpn
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Arerugi
JT  - Arerugi = [Allergy]
JID - 0241212
SB  - IM
MH  - Administration, Sublingual
MH  - Adult
MH  - *Cryptomeria
MH  - Female
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Male
MH  - Quality of Life
MH  - Rhinitis, Allergic, Seasonal/drug therapy/*therapy
EDAT- 2016/01/05 06:00
MHDA- 2016/04/02 06:00
CRDT- 2016/01/05 06:00
PHST- 2016/01/05 06:00 [entrez]
PHST- 2016/01/05 06:00 [pubmed]
PHST- 2016/04/02 06:00 [medline]
AID - 10.15036/arerugi.64.1323 [doi]
PST - ppublish
SO  - Arerugi. 2015 Dec;64(10):1323-33. doi: 10.15036/arerugi.64.1323.